Biogen Idec (BIIB)'s "Neutral" Rating Reaffirmed by Zacks Investment Research ... - LocalizedUSA

Biogen Idec (BIIB)'s "Neutral" Rating Reaffirmed by Zacks Investment Research ... LocalizedUSA Its marketed products address diseases: multiple pathology (MS), non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), Crohn’s disease (CD), chronic leucocyte leukemia (CLL) and disease of the skin . Its primary origin of other revenue is derived from ... Biogen Idec Breaking Down? TradersHuddle.com BIOGEN IDEC HAS RETURNED 15.8% SINCE SMARTREND RECOMMENDATION (BIIB) Zacks.com Biogen Idec (BIIB) Crosses Pivot constituent Support at $112.61 financial News Network Online each 8 news articles » Link To Article